JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsubayashi, H.
Right arrow Articles by Albuquerque, E. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsubayashi, H.
Right arrow Articles by Albuquerque, E. X.

Vol. 281, Issue 2, 834-844, 1997

Amantadine Inhibits Nicotinic Acetylcholine Receptor Function in Hippocampal Neurons1

Hiroaki Matsubayashi, Karen L. Swanson and Edson X. Albuquerque

Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland (H.M., K.L.S., E.X.A.), and Laboratory of Molecular Pharmacology II, Institute of Biophysics "Carlos Chagas Filho," Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (E.X.A.)

The effects of amantadine on nicotinic acetylcholine receptors (nAChRs) of hippocampal neurons were studied by recording three types of acetylcholine (ACh)-evoked currents, using the whole-cell patch-clamp technique. The rapidly desensitizing type IA nicotinic current, which is alpha -bungarotoxin-sensitive and is mediated by nAChRs bearing alpha 7 subunits, was inhibited by application of amantadine to neurons for 10 min (IC50 = 6.5 µM), but the potency of ACh (EC50 = 0.27 mM) was not affected by the drug. Amantadine (30-50 µM) attenuated the peak current amplitude in a voltage-dependent manner, with greater effect at negative than at positive membrane potentials. In contrast, the decay phase of the currents was shortened in a voltage-independent manner. When amantadine was coapplied briefly with ACh, the drug was markedly less potent (IC50 = 130 µM). Thus, the noncompetitive effects of amantadine on the type IA nicotinic current are complex, involving actions on the closed and desensitized states of the alpha 7 nAChR. The slowly desensitizing, alpha -bungarotoxin-insensitive nicotinic currents of type II, which is inhibited by dihydro-beta -erythroidine and is mediated by alpha 4beta 2 nAChRs, and of type III, which is inhibited by mecamylamine and is mediated by alpha 3beta 4 nAChRs, were also sensitive to inhibition by amantadine. The peak amplitude of type II current was reduced only slightly by 10 µM amantadine coapplied with ACh, but the decay-time constant and amplitude of the sustained current were markedly reduced. Type III current was also inhibited when amantadine was briefly coapplied with ACh. In contrast to its effects on nicotinic currents, amantadine at 10 µM did not affect currents evoked by N-methyl-D-aspartate plus glycine, gamma -aminobutyric acid, glycine or kainate. Thus, on cultured hippocampal neurons, amantadine preferentially inhibits nicotinic currents.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.